Amneal Wins Race For US NuvaRing Rival
Immediately Started Commercialization Of Contraceptive
Amneal has become the first company to secure US approval for, and to launch, a generic alternative to Merck & Co’s top-selling, off-patent NuvaRing contraceptive device in the US. Other generics developers appear to be several months behind.
